Synergistic Treatment System for Malignant Lung Tumors

A comprehensive system integrating AI, IoT, blockchain, and new materials to enhance treatment efficacy and patient outcomes for malignant lung tumors

The original patent disclosed a selective inhibitor of exon 20 insertion mutant EGFR for treating malignant lung tumors. However, it had limitations in detecting and analyzing EGFR mutations, predicting treatment efficacy, and ensuring secure data sharing. The new inventive concept addresses these limitations by integrating distinct technologies to create a more powerful system

The system comprises a genetic testing module, an AI-based analysis module, and a database for storing EGFR mutation information. The AI module predicts treatment efficacy based on the detected mutation and stored information. Additionally, the system includes an IoT-enabled sensor network for identifying potential therapeutic agents and a blockchain-based secure data sharing platform for analyzing genomic data. The system also features a nanoparticle-based delivery system for targeted delivery of the selective inhibitor, composed of a new material with enhanced biocompatibility and stability

The new inventive concept combines the selective inhibitor of exon 20 insertion mutant EGFR with AI, IoT, blockchain, and new materials to create a synergistic system that enhances treatment efficacy and patient outcomes. The integration of these distinct technologies is novel and non-obvious compared to the original patent

Alternative embodiments may include using different AI algorithms, IoT sensor networks, or blockchain platforms. Variations may include integrating additional technologies, such as machine learning or genomics platforms, to further enhance the system's capabilities

The inventive concept has significant commercial potential in the pharmaceutical and healthcare industries, particularly in the development of personalized treatment plans for malignant lung tumors